Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02209376 · ClinicalTrials.gov registry record · Phase 1
Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma
A Phase 1 study, sponsored by University of Pennsylvania.
- Terminated
- Registry status
- Phase 1
- Development phase
- 11
- Enrollment target
NCT02209376: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT02209376 is a Phase 1 study that was terminated before completion, run by University of Pennsylvania. The registered enrollment target is 11 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02209376, a Phase 1 study, was terminated before completion, sponsored by University of Pennsylvania.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 11 participants
- Enrollment target
Study Summary
An Open-Label Phase 1 Pilot Study to determine the safety and feasibility of CART-EGFRvIII (autologous T cells transduced with a lentiviral vector to express a chimeric antigen receptor specific for EGFRvIII) in the treatment of patients with EGFRvIII+ glioblastoma who have had their first recurrence as determined by standard imaging or have have residual disease after initial resection.
Interventions
- BIOLOGICAL CART-EGFRvIII T cells
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 11 participants |
| Start Date | 2014-11-18 |
| Est. Completion | 2018-04-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02209376
The ClinicalTrials.gov registry entry for NCT02209376 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CART-EGFRvIII T cells is the first listed.
NCT02209376 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02209376 about?
NCT02209376 is a clinical study titled "Autologous T Cells Redirected to EGFRVIII-With a Chimeric Antigen Receptor in Patients With EGFRVIII+ Glioblastoma". An Open-Label Phase 1 Pilot Study to determine the safety and feasibility of CART-EGFRvIII (autologous T cells transduced with a lentiviral vector to express a chimeric antigen receptor specific for EGFRvIII) in the treatment of patients with EGFRvIII+ glioblastoma who have had their first recurrenc...
What is the current status of trial NCT02209376?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 11 participants. The study started on 2014-11-18. Estimated completion is 2018-04-04.
What interventions are being tested in trial NCT02209376?
The interventions under investigation include: CART-EGFRvIII T cells (BIOLOGICAL).
Who is sponsoring clinical trial NCT02209376?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.